Halozyme Therapeutics Inc
F:RV7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Halozyme Therapeutics Inc
F:RV7
|
US |
|
Transcat Inc
F:TR8
|
US |
Intrinsic Value
The intrinsic value of 
Halozyme Therapeutics Inc (RV7) under the Base Case is 79 EUR per share.
Compared with the current market price of 117.25 EUR, the stock appears
Overvalued by 33% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Halozyme Therapeutics Does
Halozyme Therapeutics makes drug-delivery technology that helps injectable medicines move from an IV infusion to a shot under the skin. Its core product is a recombinant enzyme used with partner drugs so patients can receive certain therapies faster and more conveniently in outpatient settings. The company also develops and sells this enzyme in forms used by its pharmaceutical partners and in hospital care.
- Headquarters
- United States of America US
- Employees
- 423
- IPO date
- Jan 30, 2003
Halozyme Therapeutics has a wide economic moat
Patent protection keeps rivals from freely copying Halozyme’s injection technology, while its inclusion in approved medicines makes replacement costly and time-consuming. Together, these barriers help Halozyme retain drug-company partners and collect payments tied to their medicine sales.
Read the full moat analysis
Revenue & Expenses Breakdown
Halozyme Therapeutics Inc
Earnings Waterfall
Halozyme Therapeutics Inc
The intrinsic value for Halozyme Therapeutics Inc (RV7) under the Base Case is 79 EUR.
Compared with the current market price of 117.25 EUR, the stock appears Overvalued by 33% .